From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Human Vaccines Project Names Koff as President and CEO

by Global Biodefense Staff
April 25, 2016
Human Vaccines Project

Human Vaccines ProjectThe Human Vaccines Project has named Dr. Wayne C. Koff, Ph.D. as its first President and Chief Executive Officer (CEO). Dr. Koff joins the Project from the International AIDS Vaccines Initiative (IAVI), where he served for over 17 years, most recently as its Chief Scientific Officer.

“We are entering a transformative period in the fields of immunology and vaccine design driven by a host of groundbreaking technologies,” said Nobel Laureate Dr. Peter Doherty, a member of the Project’s Scientific Steering Committee. “The time has come for a large-scale scientific initiative such as the Human Vaccines Project to harness these technologies towards accelerating development of next generation vaccines and immunotherapies. Those of us who have had the privilege of working with him in the past are delighted that Dr. Wayne Koff will be the CEO of this extraordinary new initiative and look forward to extending our association in this exciting enterprise aimed at improving the life prospects of all human beings.”

While at IAVI, Dr. Koff played a central role in the creation and expansion of IAVI’s R&D program that spanned R&D efforts in 20 plus countries, and included the establishment of the Neutralizing Antibody Consortium in 2001 that went on to discover a wide range of potent and new HIV broadly neutralizing antibodies that have led to the identification of novel and promising targets for HIV vaccine discovery. Prior to working at IAVI, Dr. Koff served as Vice President of Vaccine Research and Development at United Biomedical Inc. (UBI), which conducted some of the first HIV vaccine trials in the developing world.

Dr. Koff also served as Chief of the Vaccine Research and Development branch, Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID) for the National Institutes of Health (NIH).

“It is becoming increasingly clear that by directing the human immune system through vaccines and immunotherapies, we now have the potential to prevent or treat a wide range of complex diseases from HIV, to emerging pathogens such as Zika, to multiple autoimmune disorders and cancers,” said Dr. Koff. “Our goal at the Project is accelerate product development by overcoming key limitations in our current understanding of human immunity. By creating a unique global research consortium, consisting of pharma and biotech companies, vaccine research centers, industry players in artificial intelligence and machine learning, government and NGO laboratories, we have the potential for ushering in a new era of vaccine and immunotherapeutic development.”

The Project has recently completed its catalytic stage of development where it established key partnerships of its global consortium, and secured startup financing. Over the coming months the Project will launch its first scientific studies, establish its bioinformatics and data management core, and complete the development of its consortium.

“Dr. Koff has been a leader in the field of vaccines for over 25 years, and we are delighted to announce that he will be serving as the organization’s President and CEO,” said Dr. Stanley Plotkin, Board Chair of the Human Vaccines Project and Professor Emeritus at the University of Pennsylvania. “As Founder of the Project, and with extensive experience in building innovative global research consortia, Dr. Koff is the ideal candidate to lead this ambitious effort which seeks to accelerate vaccine development for a wide range of diseases through a more comprehensive understanding of human immunity.”

From Our Partners
Tags: BioinformaticsLeadership

Related Posts

Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization
Biodetection

Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization

March 19, 2022
There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness
Industry News

Appili Awarded $10M in New Biodefense Funding for Tularemia Vaccine Candidate

March 3, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC